Oculis (NASDAQ:OCS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $39.00 price objective on the stock. HC Wainwright‘s target price indicates a potential upside of 411.14% from the stock’s current price.
OCS has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research report on Thursday, October 15th. JPMorgan Chase & Co. cut their price objective on Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Finally, Guggenheim reduced their price objective on Oculis to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.57.
Check Out Our Latest Report on Oculis
Oculis Price Performance
OCS opened at $7.63 on Tuesday. The company has a quick ratio of 10.41, a current ratio of 10.41 and a debt-to-equity ratio of 0.01. Oculis has a 52-week low of $6.78 and a 52-week high of $34.47. The company has a 50 day moving average of $8.65 and a two-hundred day moving average of $17.77. The company has a market cap of $442.39 million, a P/E ratio of -4.46 and a beta of 0.67.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.10. Oculis had a negative net margin of 8,613.92% and a negative return on equity of 39.24%. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.26 million. On average, analysts expect that Oculis will post -1.83 earnings per share for the current year.
Institutional Trading of Oculis
Hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC acquired a new position in shares of Oculis during the third quarter worth $134,000. Goldman Sachs Group Inc. boosted its stake in shares of Oculis by 103.9% in the third quarter. Goldman Sachs Group Inc. now owns 141,688 shares of the company’s stock valued at $1,323,000 after purchasing an additional 72,186 shares during the period. Checkpoint Capital L.P. acquired a new stake in Oculis during the 3rd quarter valued at $929,000. Alps Advisors Inc. grew its holdings in Oculis by 40.7% during the 3rd quarter. Alps Advisors Inc. now owns 81,619 shares of the company’s stock valued at $762,000 after purchasing an additional 23,600 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Oculis during the 3rd quarter valued at $74,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.
Oculis Company Profile
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Featured Articles
- Five stocks we like better than Oculis
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
